The biologic revolution finally arrived for atopic dermatitis (AD) in 2017, with the approval of dupilumab, heralding a new era with many other agents in active development.1,2 Significant improvement in disease severity measures and a number of quality-of-life measures have raised the bar for AD treatment, mirroring the more stringent treatment goals that have been defined for patients with psoriasis.3